시장보고서
상품코드
1480863

세계의 경피증 진단과 치료법 시장

Scleroderma Diagnostics and Therapeutics

발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 194 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 경피증 진단과 치료법 시장은 2030년까지 28억 달러에 도달

2023년에 21억 달러로 추정되는 세계의 경피증 진단과 치료법 시장은 2023-2030년 CAGR 4.1%로 성장하며, 2030년에는 28억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 국한형 경피증 진단과 치료법은 CAGR 4.5%를 기록하며, 분석 기간 종료까지 18억 달러에 달할 것으로 예측됩니다. 전신피부경화증 진단과 치료법 분야의 성장은 향후 7년간 CAGR이 3.5%로 추정되고 있습니다.

미국 시장은 6억 2,700만 달러로 추정, 중국은 CAGR 3.8%로 성장 예측

미국의 경피증 진단과 치료법 시장은 2023년에 6억 2,700만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2023-2030년의 분석 기간에 CAGR 3.8%로 추이하며, 2030년까지 4억 8,630만 달러의 시장 규모에 달할 것으로 예측되고 있습니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 각각 2023-2030년 3.7%와 3.5%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 3.1%로 성장할 것으로 예측되고 있습니다.

2024년의 매력적인 신규 리포트 기능 소개

인플루언서 관여 통계에 대한 풀 액세스

디지털 아카이브와 "MarketGlass" 조사 플랫폼에 대한 무료 액세스. Global Industry Analysts, Inc.의 독자적인 MarketGlass 플랫폼은 전 세계 전문가의 창조성과 시장 지식을 통합적 및 협조적으로 활용할 수 있도록 지원합니다. Global Industry Analysts, Inc.의 최첨단 툴은 시장 참여 기업의 프라이버시와 ID를 보호하면서 세계 클래스의 시장 전망을 가져옵니다. 리포트내 수치, 통계, 시장에 관한 설명은 이 분야의 전문가 및 인플루언서에 의해 공유된 완전하게 큐레이트된 인사이트에 기반하고 있습니다.

실시간 데이터 시뮬레이터·툴 및 맞춤형 리포트 작성 기능을 갖춘 인터랙티브 앙케이트에 참가할 수 있습니다.

기업간 스마트한 의견교환을 위한 피어 협업·인터랙티브 플랫폼에 대한 풀 클라이언트 액세스

1년간 무료 리포트 업데이트

주요 기업의 세계 시장 점유율을 포함한 경쟁 커버리지

복수 지역에 걸친 기업 시장 입지 분석(호조/활발/니치/마이너)

전문가/인플루언서 인터뷰, 팟캐스트, 프레스 발표, 이벤트 기조 강연의 YouTube 비디오에 대한 액세스

2024년 세계 경제에 기대하는 것

금융긴축과 이에 따른 금리 상승에 의해 발생하는 지정학적, 경제적 불안정성이 2024년 격동의 상황을 야기할 것으로 생각됩니다. 중동에서의 적대 행위 및 더욱 더 빈발하는 기후 재해 등 몇개의 요인이 회복의 길에 계속 압력을 가할 것으로 생각됩니다. 이러한 리스크 가운데 디스인플레이션의 조짐과 고질적인 인플레이션에 대한 불안감 완화, 공급망 정상화, 에너지 비용의 변동성에도 불구하고 가격 조정 등 몇 가지 긍정적인 요소도 구체화되고 있습니다. 인도 및 미국을 비롯한 G21 국가의 선거는 자본 흐름 및 투자전략에 영향을 미칠 가능성이 있습니다. 인도가 세계 투자처로서 주목받는 한편, 미국을 기반으로 하는 하이테크 기업은 재능과 자본의 역동적인 에코시스템에 의해 지원되며 계속 우위를 유지할 것으로 생각됩니다. 실리콘밸리를 비롯한 하이테크 기회는 국내 경제가 감속하고 있으나 안정적이며, 규제 환경도 정비되고 있는 것으로 인해 고성장 가능성을 요구하는 투자자에게 계속 매력적입니다. 유럽은 금융긴축정책과 경기후퇴 리스크와의 싸움이 계속되며, 영국은 전망이 가장 어렵고, 2024년 경기후퇴 리스크가 가장 높습니다. 중국은 정부지출과 개인소비의 개선에 의지한 성장이 기대되며 계속해서 와일드 카드로 남아 있습니다. 불안정한 환경은 투자자와 기업 모두에게 기회와 과제를 둘 다 제공할 것으로 생각됩니다. 성장에 대한 촉매로서 변동성을 수용하는 것과 함께 투자 판단 결정에서 민첩성과 전략적 선견성이 생존을 위해 여전히 중요할 것입니다.

조사 대상 기업의 예(총 42건)

  • Actelion Pharmaceuticals Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Corbus Pharmaceuticals Holdings, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cytori Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Pfizer, Inc.
  • Sanofi SA

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 세계의 기타 지역

제4장 경쟁

KSA 24.06.03

Global Scleroderma Diagnostics and Therapeutics Market to Reach $2.8 Billion by 2030

The global market for Scleroderma Diagnostics and Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 4.1% over the period 2023-2030. Localized Scleroderma Diagnostics and Therapeutics, one of the segments analyzed in the report, is expected to record 4.5% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Systemic Scleroderma Diagnostics and Therapeutics segment is estimated at 3.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $627 Million, While China is Forecast to Grow at 3.8% CAGR

The Scleroderma Diagnostics and Therapeutics market in the U.S. is estimated at US$627 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$486.3 Million by the year 2030 trailing a CAGR of 3.8% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.7% and 3.5% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 42 Featured) -

  • Actelion Pharmaceuticals Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Corbus Pharmaceuticals Holdings, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cytori Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Pfizer, Inc.
  • Sanofi SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Scleroderma Diagnostics and Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Immunosuppressive Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Immunosuppressive Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Endothelin receptor antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Endothelin receptor antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Scleroderma Diagnostics and Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Localized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Localized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Systemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Systemic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • JAPAN
    • Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • CHINA
    • Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • EUROPE
    • Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • FRANCE
    • Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • GERMANY
    • Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Scleroderma Diagnostics and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Drug Class - Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Immunosuppressive Agents, Endothelin receptor antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Scleroderma Diagnostics and Therapeutics by Disease Type - Localized and Systemic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Scleroderma Diagnostics and Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Localized and Systemic for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제